Articles On Biotron (ASX:BIT)

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

It’s easy to just think of Pfizer and AstraZeneca as the only two companies fighting COVID-19 in Australia. But Biotron ... Read More The post AstraZeneca’s COVID-19 fight hits the skids; ASX small cap Biotron says ‘We’re on track’ appeared...

Summary ASX 200 listed retail company Unibail-Rodamco-Westfield disclosed a €9.0 billion RESET plan for strengthening its balance sheet and improving financial flexibility. Financial service provider FlexiGroup had completed Retail Enti...

The hunt for a COVID-19 vaccine is ramping up. We learnt yesterday that the government has spent $1.7 billion on potential treatments. Hedging their bets on some $84 million worth of doses that will be ready for free rollouts by 2021... The...

In afternoon trade the S&P/ASX 200 Index (ASX: XJO) is on course to snap its losing streak with a solid gain. At the time of writing the benchmark index is up 0.4% to 5,949.2 points. Four shares that are climbing more than most today a...

The chase for effective COVID-19 treatments is well and truly on after biotech company Biotron (ASX: BIT) confirmed it intends to harness its proprietary compounds to develop a treatment for SARS-CoV-2, the coronavirus that causes the COVID...

Pharmaxis (ASX:PXS) and Biotron (ASX:BIT) have gone in polar opposite directions in 2020 and today the gap widened further. Biotron has now nearly doubled in 2020 while Pharmaxis has nearly halved. Pharmaxis ended 2019 with a big blow which...

The Biotron Limited (ASX: BIT) share price has rocketed higher on Monday after the release of an update. In early trade the clinical stage biotechnology company’s shares were up as much as 47% to 14 cents. They have since given back much o...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week The life s...

A quick wrap of the ASX’s key winners and losers on Tuesday, July 7. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made market-moving announcements during the day. Today 571 stocks rose, 750 declined and 786...

The Biotron Limited (ASX: BIT) share price soared by 30% today, after the biotechnology company released new data regarding the effectiveness of its lead antiviral drug BIT225, used for fighting HIV-1 infections. The Biotron share price is...

A quick wrap of the key winners and losers on Monday, July 6. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made market-moving announcements during the day. Today 712 stocks rose, 576 declined and 819 were u...

Biotron’s (ASX: BIT) lead candidate HIV-1 drug BIT225 has been shown to boost the body’s immune response to HIV by inhibiting viral protein Vpu, while also having an anti-viral effect. The company is presenting new data on BIT225’s positive...

Biotron (ASX:BIT) has announced it will present the latest data on BIT225 HIV-1 at the 23rd International AIDS Conference (AIDS 2020: Virtual) in July.

Typically patients with HIV need to stay on treatment for life but that may no longer be the case if Biotron’s (ASX:BIT) anti-HIV therapy stacks up. The biotech has found that its anti-HIV therapy can restore immune functions in HIV patient...

The Biotron Limited (ASX: BIT) share price is soaring higher this morning after the small-cap ASX healthcare share released more data in relation to the effectiveness of its antiviral drug, BIT225. After rocketing as much as 21.7% higher i...

The S&P/ASX 200 index (ASX: XJO) has followed the lead of U.S. markets and is tumbling lower on Thursday. In morning trade the benchmark index is down 2.4% to 5,588.2 points. Four shares that have not let that hold them back are listed...

Jatenergy (ASX:JAT) shares are surging after the company said it booked record sales and revenue in February, as Chinese buyers sucked up its milk products. Revenue was $8.3m for the month. The board has lifted full year guidance from $36m...

Clinical stage company Biotron (ASX: BIT) is preparing to present results from its ongoing Phase 2 trial into its lead BIT225 drug at the annual Conference on Retroviral and Opportunistic Infections (CROI) this week with new data showing th...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

There are dozens of vaccines, antiretrovirals and new supportive therapies being feverishly tested against COVID-19, and researchers say new technologies are enabling them to move faster than ever before. COVID-19, a member of the coronavir...

As with the early medical cannabis plays, a cluster of ASX-listed stocks has wasted little time attaching itself to the ‘c’ word. We’re talking of course about the coronavirus COVID-19 but sadly not another ‘c’ word: cure. Or not yet. Accor...

The spread of coronavirus has infected global share markets with the contagion of fear. The S&P/ASX 200 Index (INDEXASX: XJO) has fallen more than 10% in the last fortnight as investors flee to safe havens. This week, the Reserve Bank...

In February, mounting coronavirus-led uncertainty finally culminated in a late-month share price bloodbath. After a 3 per cent gain in January, the S&P/ASX Emerging Companies Index – which gauges the health of the microcap sector – had...

Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast. In this episode Tim chats with Dr Michelle Miller, chief executive of...

As the coronavirus death toll rises to more than 1,000 and the World Health Organisation labels it a global health emergency, share markets are feeling the impact of the outbreak with Australian ASX-listed stocks not immune to the damage. C...

With the market returning to form and charging higher on Tuesday, it will come as no surprise to learn that a good number of shares pushed higher. Some that pushed so hard they ended up reaching 52-week highs or better are listed below. He...

Today’s session proved much kinder to the Aussie market, delivering strong gains across the board as China’s factories came back online. While the dollar remained fairly stagnant, sectors, futures and indices did a 180, rallying to rever...

Australian shares rose to a two-week high as investors weighed positive overnight leads against the impact of bushfires and the coronavirus on company earnings. The ASX 200 advanced 51 points or 0.7 per cent to 7063, the index’s highest...

Biotron (ASX:BIT) has joined the global search for a coronavirus vaccine by confirming it is evaluating several compounds, including the new novel strain known as 2019-nCoV.

A fresh decade-low for the dollar ended today’s session on a weak note, leaving Australian markets in the red. Despite attempts to climb against the greenback later in the day, the dollar was worth as little as 66.6 US cents this morning...

As the coronavirus death toll overtakes the 2002 SARS outbreak, demand for Holista Colltech’s (HCT) NatShield sanitising spray has risen once again Holista will now ship a further 90,000 units to Kuala Lumpur after the original top-up of 6...

The Biotron Limited (ASX: BIT) share price has been a standout performer on the Australian share market this week. On Friday afternoon the clinical stage biotechnology company’s shares have rocketed higher for a second day in a row. At the...

The S&P/ASX 200 index is on course to end the week deep in the red. In afternoon trade the benchmark index is down 0.6% to 7,007.2 points. Four shares that have not let that hold them back today are listed below. Here’s why they are st...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Global markets continued their rebound today as commodity prices reversed last week’s losses. Overnight, European and American markets had another happy trading session, setting the ASX up for its third straight rise. Our benchmark...

Australia’s S&P/ASX 200 (Index: ^AXJO)(ASX: XJO) and ALL ORDINARIES (Index: ^AXAO) (ASX: XAO) indices finished higher on Thursday. Here’s a short recap of the Australian market: S&P/ASX 200 (Index: ^AXJO) (ASX: XJO) higher 1.05%...

The S&P/ASX 200 index has followed the lead of U.S. markets and is pushing higher again. In afternoon trade the benchmark index is up 0.8% to 7,030.9 points. Four shares that are climbing more than most today are listed below. Here’s w...

Following market speculation in January, Biotron (BIT) has emerged as a potential runner in the race to find the coronavirus cure The Biotech specialist said it has 30 antivirus compounds which show potential in their ability to treat the...

As global authorities race to contain the outbreak of coronavirus, Aussie healthcare stock Biotron (ASX:BIT) thinks it may be able to help. The company’s primary focus is anti-virus medications for HIV and Hepatitis B, via the development o...

Australian clinical stage company Biotron (ASX: BIT) has announced it will commence the evaluation of “several promising compounds” which could target various strains of coronavirus, including the deadly 2019-nCoV creating a global health i...

One of the best performers on the ASX on Thursday has been the Biotron Limited (ASX: BIT) share price. In morning trade the clinical stage biotechnology company’s shares rocketed 28% higher to 10.5 cents. They have since pulled back a touc...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Aussie shares rose for a second day after Chinese stimulus measures helped a global market rebound gather momentum overnight. The ASX 200 briefly regained the 7000 level before paring its gain to 27 points or 0.4 per cent at 6976. At its...

By Tim Boreham, Editor, The New Criterion Stocks that tap the disaster zeitgeist With the stock market off to a galloping start in 2020 – at least before the coranavirus sniffles set in — most investors would have been content with a passiv...

A rebound on Wall Street and the possibility of a surprise rate cut this afternoon helped the share market inch higher despite pressure on resource stocks. The ASX 200 gained momentum after a turgid opening hour, rising 34 points or 0.5...

The Australian share market tumbled 80 points as oil touched its lowest level in a year and Chinese markets re-opened with massive losses. The ASX 200 surrendered its grip on 7,000, falling 1.1 per cent to 6933 by mid-session. At its nad...

Coronavirus scares and bushfire reconstruction play into the stock prices of small caps Biotron and Johns Lyng.

Rising coronavirus fears have ignited demand for Hollister Colltech’s (HTC) NatShield Sanitiser in Kuala Lumpur The company has already sold out of its sanitising spray in Malaysia’s capital To combat rising demand for Natshield, Holista p...